logo-loader

Scancell Holdings PLC 'delighted' with success of £6.1mln fundraiser

Published: 02:56 01 Apr 2016 EDT

CancerHeadline
The firm's technology uses the body's immune system to fight cancer

Scancell Holdings PLC (LON:SCLP) said it had successfully raised £6.1mln via a placing and open offer of shares with new and existing investors.

The cash will be used to accelerate the development of both the ImmunoBody and Moditope platform technologies that help the body’s own immune system fight cancer.

The fundraise was done in two tranches. A total of £3.4mln-worth of stock was placed at 17p a share.

Existing shareholders were also given the opportunity to follow their money in what’s called an open offer, which brought in another £2.7mln.

Chairman John Chiplin said he was “delighted” at the response from investors.

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview...

on 09/19/2023